[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645726":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":32,"locations":37,"responsibleParty":57,"collaborators":10,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":25,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":10,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":86,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Università Vita-Salute San Raffaele","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Familial pancreatic cancer (FPC)",null,"This term refers to individuals who are at a higher risk of developing pancreatic cancer based on their family history. There are two main risk categories:\n\n* 2 relatives with pancreatic cancer, who are first-degree relative of each other, and at least one should be a first degree relative of the individual for whom surveillance is being considered\n* 3 or more relatives with pancreatic cancer, regardless of the degree",[13],"Diagnostic Test: PANXEON",{"label":15,"type":10,"description":16,"interventionNames":17},"Hereditary pancreatic cancer (HPC)","This terms encompasses all individuals who are at an increased risk of developing pancreatic cancer based on the presence of a pathogenic (or likely pathogenic) germline variant. More specifically:\n\n* All individuals with a pathogenic (or likely pathogenic) germline variant in Serine\u002FThreonine Kinase 11 (STK11), cyclin-dependent kinase inhibitor 2A (CDKN2A), Ataxia-Telangiectasia Mutated (ATM), and Breast cancer type 2 (BRCA2) genes, regardless of their family history of pancreatic cancer\n* Individuals who have both (i) a pathogenic (or likely pathogenic) germline variant in Breast cancer type 1 (BRCA1), Partner and Localizer of BRCA2 (PALB2), Mutator L Homolog 1 (MLH1), Mutator S Homolog 2 (MSH2), Mutator S Homolog 6 (MSH6), Postmeiotic Segregation 1 Homolog 2 (PMS2), or Epithelial Cell Adhesion Molecule (EPCAM) genes; and (ii) at least one relative diagnosed with pancreatic cancer",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Mucinous Pancreatic Neoplasms (MPN)","This term refers collectively to cystic lesions of the pancreas that confer an increased risk of developing pancreatic cancer. Collectively, this term encompasses both Intraductal Pancreatic Mucinous Neoplasms (IPMN) and Mucinous Cystic Neoplasias (MCNs)",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","PANXEON","A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples",[9,15,19],[29],{"name":30,"affiliation":5,"role":31},"Alessandro Mannucci, MD","PRINCIPAL_INVESTIGATOR",[33],{"name":30,"role":34,"phone":35,"phoneExt":10,"email":36},"CONTACT","0226437262","mannucci.alessandro@hsr.it",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"IRCCS San Raffaele Hospital","RECRUITING","Milan","MI","20132","Italy","IT",{"type":47,"coordinates":48},"Point",[49,50],12.59836,42.78235,{"lat":50,"lon":49},[53],{"name":54,"role":34,"phone":55,"phoneExt":10,"email":56},"Giulia Martina Cavestro, MD, PhD","0226437217","cavestro.giuliamartina@hsr.it",{"type":31,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Alessandro Mannucci","Principal Investigator (AIRCS Start-Up #32233)","100645726","a-liquid-biopsy-for-pancreatic-cancer-early-detection-and-disease-monitoring-100645726",false,"NCT07700992","A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring","An Exosome-based and Machine-learning-powered Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring","Inclusion Criteria:\n\n* Adult men or women aged ≥18 years at the time of plasma sample collection.\n* Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to familial pancreatic cancer or hereditary pancreatic cancer syndrome\n* Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to the presence of one (or more) mucinous pancreatic cystic lesion(s).\n* Availability of stored plasma samples collected as part of routine clinical care or surveillance and archived in the institutional biobank.\n* Availability of relevant clinical and demographic data in institutional medical records sufficient to address study objectives.\n* Prior provision of informed consent for biobanking and research use of biological samples and data\n\nExclusion Criteria:\n\n* Absence or insufficient quality\u002Fquantity of stored plasma samples for laboratory analysis.\n* Lack of clinical data required for cohort classification and\u002For outcome assessment.\n* History of pancreatic surgery or interventional procedures prior to plasma sample collection.\n* Concurrent active malignancy at the time of sample collection, other than non-melanoma skin cancer.\n* Samples collected outside routine clinical care or not compliant with institutional biobanking and data protection policies.","ALL","18 Years","99 Years",{"count":71,"type":72},600,"ESTIMATED","OBSERVATIONAL","Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are currently limited to imaging-based surveillance (MRI and endoscopic ultrasound) in selected high-risk populations, but these approaches are invasive, costly, and suboptimal in sensitivity. The aim of this study is to evaluate circulating cell-free and exosome-bound microRNAs as non-invasive biomarkers of PDAC risk and disease biology",[76,77,78,79,80,81,82,83,84,85],"Familial Pancreatic Cancer","Familial Pancreatic Carcinoma","Hereditary Pancreatic Cancer","Hereditary Pancreatitis","Pancreas Cancer","Pancreas Neoplasm","Pancreas Adenocarcinoma","Pancreas Cyst","Pancreatic Neoplasms","Intraductal Papillary Mucinous Neoplasm",[87,88],"Early detection","Liquid biopsy","2026-07-13",{"date":91,"type":92},"2026-07-14","ACTUAL",{"date":94,"type":92},"2026-06-03",{"date":96,"type":72},"2032-01-30",{"name":5,"class":6},1]